Pay in 4 interest-free payments of $7.28 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Moreover, the SURPASS programme demonstrated that tirzepatide 15 mg is more efficacious in glycaemic control for people with T2D compared to insulin therapies as well as GLP-1 mono-agonists including semaglutide 1 mg and dulaglutide 1.5 mg
5/5 ( )
Both are weekly injections and require medical supervision
In some cases, supplements or dietary changes may be necessary
For patients with diabetes, this is especially valuable for eye health since diabetes damages the eyes over time and potentially leads to vision loss or blindness
US$ 26.50
US$ 22.69
US$ 24.43
